Dosing clopidogrel based on CYP2C19 genotype and the effect on platelet reactivity in patients with stable cardiovascular disease. - Wikidata - awgldk - TriplyDB

Dosing clopidogrel based on CYP2C19 genotype and the effect on platelet reactivity in patients with stable cardiovascular disease.

Dosing clopidogrel based on CYP2C19 genotype and the effect on platelet reactivity in patients with stable cardiovascular disease.

http://www.wikidata.org/entity/Q34633709

about

Pharmacometabolomics-aided Pharmacogenomics in Autoimmune Disease Personalized antiplatelet therapy with P2Y12 receptor inhibitors: benefits and pitfalls Clopidogrel and warfarin pharmacogenetic tests: what is the evidence for use in clinical practice?Clinical utility of pharmacogenetic biomarkers in cardiovascular therapeutics: a challenge for clinical implementation Future translational applications from the contemporary genomics era: a scientific statement from the American Heart Association Potential Usefulness of Clopidogrel Pharmacogenetics in Cerebral Endovascular Procedures and Carotid Artery Stenting.Guided antithrombotic therapy: current status and future research direction: report on a National Heart, Lung and Blood Institute working group.Interplay between genetic and clinical variables affecting platelet reactivity and cardiac adverse events in patients undergoing percutaneous coronary intervention.Effectiveness of clopidogrel dose escalation to normalize active metabolite exposure and antiplatelet effects in CYP2C19 poor metabolizers.Mutational analysis clopidogrel resistance and platelet function in patients scheduled for coronary artery bypass grafting.Drug-gene interactions: inherent variability in drug maintenance dose requirements Pharmacogenetic selection of volunteers increases stringency of bioequivalence studies; the case of clopidogrel Pharmacogenomics of drug-metabolizing enzymes: a recent update on clinical implications and endogenous effects.Insurance coverage policies for personalized medicine.High Platelet Reactivity in Patients with Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention: Randomised Controlled Trial Comparing Prasugrel and Clopidogrel Neurointerventional Stenting and Antiplatelet Function Testing: To Do or Not to Do?Association of Cytochrome P450 Genetic Variants with Clopidogrel Resistance and Outcomes in Acute Ischemic Stroke.Relating human genetic variation to variation in drug responses.Pharmacodynamic effect of cilostazol plus standard clopidogrel versus double-dose clopidogrel in patients with type 2 diabetes undergoing percutaneous coronary intervention Personalized medicine: is it a pharmacogenetic mirage?Omics Screening for Pharmaceutical Efficacy and Safety in Clinical Practice Roles of CYP2C19 Gene Polymorphisms in Susceptibility to POAG and Individual Differences in Drug Treatment Response.Pharmacogenomic testing and antithrombotic therapy: ready for prime time?Pharmacogenetics and cardiovascular disease--implications for personalized medicine Physician response to implementation of genotype-tailored antiplatelet therapy.Representation of older adults in the late-breaking clinical trials American Heart Association 2011 Scientific Sessions Advances in our understanding of "resistance" to antiplatelet agents for prevention of ischemic stroke Genetics as a molecular window into recovery, its treatment, and stress responses after stroke Pharmacogenetic testing: Current Evidence of Clinical Utility.Pharmacogenomics in clinical practice and drug development.Expert position paper on the role of platelet function testing in patients undergoing percutaneous coronary intervention.Clinical pharmacokinetics of clopidogrel and its metabolites in patients with cardiovascular diseases.Genetic Polymorphism of CYP2C19 and Inhibitory Effects of Ticagrelor and Clopidogrel Towards Post-Percutaneous Coronary Intervention (PCI) Platelet Aggregation in Patients with Acute Coronary Syndromes.Prevalence of clinically actionable genotypes and medication exposure of older adults in the community.Clinically actionable genotypes among 10,000 patients with preemptive pharmacogenomic testing Acute coronary syndromes in 2011: Walking the tightrope between efficacy and bleeding.Genetic determinants of response to cardiovascular drugs.Genetic and non-genetic factors affecting the response to clopidogrel therapy.Antithrombotics for secondary prevention of noncardioembolic ischaemic stroke.Antithrombotic therapy in patients with acute coronary syndrome and diabetes mellitus.

P2860

Q26748481-7BED2E8B-26C5-4344-934E-CD05422A5EAB Q26775125-0FD9DD2C-B2D2-4E04-9125-18E024781DFE Q26823542-5A53FAC8-6EB3-4790-BCF8-8C90E3C67CB8 Q27011524-15E6B577-6751-43C8-B0B6-9B659E341CF4 Q30359686-51BD6665-C755-42F3-8732-8E3344C37B57 Q33818356-E9BD16A5-4ECF-446B-9294-C8E2B1D569DF Q33863833-A8D74454-F7E1-49F2-A2BF-8EF78E7672FA Q33933475-70FAB8F3-9237-4AFF-9F02-4E805B388E4F Q33963651-0035965B-86E1-47B7-95BF-6A21D635673A Q34108764-AFD227C6-3EC8-41B2-846F-3CFD19F03373 Q34154939-DBE1FF18-EEF0-4AEF-922D-9EE20587EDE4 Q34228913-44040209-81C2-45CF-8700-F23873EC36B0 Q34307589-0F0AE164-1B0D-40B6-AC3B-B5F22524CE31 Q34608654-8458FC0E-6B3F-4D71-9D6D-EC2EB2A00F7A Q35758891-657EF3EC-F350-486E-8BCC-C2F7ED266694 Q35905832-AD4F1F2F-5B93-4D67-874E-D50AA02ACEBB Q35951677-0B5DE641-3889-468A-B82B-664700A62386 Q36252524-D0B6FBEE-EF15-4199-928C-B0A89FFF7ABF Q36334515-A90A5B6B-997A-4E52-B626-902FE13ED802 Q36336007-978F2582-1356-4A6D-9F06-B294EAC34CD0 Q36477760-6BD6FD9B-4156-4B6A-9A2B-D289E4AA2495 Q36532363-8A94DB29-B63C-40E1-812A-EACFC6CF5F3E Q36919495-AAEB1DB0-F971-43DE-ADB7-8C3FA0704C83 Q36974672-BDA2BEF9-6F72-4676-8D87-4ED42FA74CFA Q36984543-893FBA0C-75E2-4A38-B218-81D18B2CC32B Q37026004-B45E56DA-0AE3-47D5-870C-39E5AAD7B97E Q37051838-CD3D6B2C-5F3C-4208-AF1F-F4647214DEEB Q37088174-22441E6E-5895-448A-8EAE-971E72171050 Q37151528-CB6B7AB0-BDF8-4A69-92F9-71B306820D81 Q37284234-4FD85B79-753B-4F28-871E-48E619A9CB69 Q37497555-A0A2D472-839A-425B-9ED8-2278C0DAEA6D Q37506535-2B8F4A10-1609-4942-AE95-A6A41E07A918 Q37530040-900C186D-0C77-46A0-807D-04313AACB619 Q37626738-580951F5-963F-407D-9D6A-2C24AA9BFEC3 Q37652863-25113D33-63E1-4517-8D53-131666D4A227 Q37969893-D2443D7D-FB89-49A6-8730-66AF56F88B0F Q37989811-045ED46C-E7F4-4572-893C-9707DCF28FD6 Q37991382-A3C41C7C-B34B-439B-9CB4-F92A47EBD5E8 Q37992812-D4575464-315E-4509-B13D-F813FA3654C4 Q37997963-613418B2-F98B-4116-8CC0-17803B12C38D

P2860

Dosing clopidogrel based on CYP2C19 genotype and the effect on platelet reactivity in patients with stable cardiovascular disease.

http://www.wikidata.org/entity/Q34633709

description

2011 nî lūn-bûn

@nan

2011 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Dosing clopidogrel based on CY ...... stable cardiovascular disease.

@ast

Dosing clopidogrel based on CY ...... stable cardiovascular disease.

@en

Dosing clopidogrel based on CY ...... stable cardiovascular disease.

@nl

type

label

Dosing clopidogrel based on CY ...... stable cardiovascular disease.

@ast

Dosing clopidogrel based on CY ...... stable cardiovascular disease.

@en

Dosing clopidogrel based on CY ...... stable cardiovascular disease.

@nl

prefLabel

Dosing clopidogrel based on CY ...... stable cardiovascular disease.

@ast

Dosing clopidogrel based on CY ...... stable cardiovascular disease.

@en

Dosing clopidogrel based on CY ...... stable cardiovascular disease.

@nl

P1433

Q34633709-72A905A0-7232-4946-A573-E43CE826FBFE

P1476

Q34633709-4765B6AD-B0D4-4338-8686-F9F7D62E4FEB

P2093

Q34633709-272AA81C-6A9E-42D5-A82D-D92A7938A17F

Q34633709-27A0FA20-F15B-48B2-B214-6708ABA7782D

Q34633709-32CFF281-A7B3-43D7-81D5-5F268AC473CE

Q34633709-339C6A6B-0443-4453-9B8E-7BEA5FD987BF

Q34633709-6132A661-D6D7-4AB6-9D61-E31616E66AA5

Q34633709-66232411-8DB4-4A56-A44A-AE5285395902

Q34633709-95D9CA07-6B47-4220-8D39-53AB9B461C9B

Q34633709-9C365CC7-E0A1-42DB-AE59-C89897DA77EF

Q34633709-A54BBA0F-7808-4964-82BC-8DA5085DFEC3

Q34633709-AA77C1D5-95F8-4347-A7F8-EF28C60ECF07

P304

Q34633709-FF9BF2F9-EB1D-4D66-A286-9E74DB056C4A

P31

Q34633709-DA3EF1F3-84EE-445A-8B09-AC17F993BBB7

P356

Q34633709-45A01CF5-8196-4B10-A493-6C9AE2F0FAF7

P407

Q34633709-29E6EFBF-C05F-421A-8493-9D5BA2848653

P433

Q34633709-12584269-2079-4DB0-9D76-02E72E929DD4

P478

Q34633709-C3B3278F-34A2-4D6C-9992-2065727239A9

P577

Q34633709-11D13062-F83F-4DD9-BB56-C1E90F734BCC

P5875

Q34633709-6626CB15-9AC8-4BDF-BA66-0DDBD3C10D22

P698

Q34633709-4533DA0E-D2CE-4802-82D3-46F7456B72D7

P921

Q34633709-4CB47707-8508-49E9-926E-67D9A1E0CC3B

Q34633709-8B348221-739C-48EF-A498-F14D319B0D5B

Q34633709-CD17611A-73C1-4B74-80E3-D3A40AA5E15B

P356

P1433

Journal of the American Medical Association

P1476

Dosing clopidogrel based on CY ...... stable cardiovascular disease.

@en

P2093

Alan D Michelson

http://www.w3.org/2001/XMLSchema#string

Andrew L Frelinger

http://www.w3.org/2001/XMLSchema#string

Benjamin M Scirica

http://www.w3.org/2001/XMLSchema#string

Charles Contant

http://www.w3.org/2001/XMLSchema#string

Christian T Ruff

http://www.w3.org/2001/XMLSchema#string

Dean J Kereiakes

http://www.w3.org/2001/XMLSchema#string

Dominick J Angiolillo

http://www.w3.org/2001/XMLSchema#string

Janina A Longtine

http://www.w3.org/2001/XMLSchema#string

Jessica L Mega

http://www.w3.org/2001/XMLSchema#string

Marc S Sabatine

http://www.w3.org/2001/XMLSchema#string

P304

2221-2228

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1001/JAMA.2011.1703

http://www.w3.org/2001/XMLSchema#string

P407

P433

20

http://www.w3.org/2001/XMLSchema#string

P478

306

http://www.w3.org/2001/XMLSchema#string

P577

2011-11-16T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51803596

http://www.w3.org/2001/XMLSchema#string

P698

22088980

http://www.w3.org/2001/XMLSchema#string

P921

cardiovascular disease